PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933329
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933329
The global interventional oncology market is experiencing consistent growth due to the rising global cancer burden and increasing preference for minimally invasive cancer treatment procedures. In 2025, the global interventional oncology market was valued at USD 2.34 billion. The market is projected to grow from USD 2.53 billion in 2026 and reach USD 4.77 billion by 2034, registering a CAGR of 8.25% during the forecast period (2026-2034).
North America dominated the global interventional oncology market with a 42.20% market share in 2025, driven by advanced healthcare infrastructure, high cancer prevalence, and early adoption of image-guided minimally invasive oncology procedures.
Interventional oncology involves the diagnosis, treatment, and palliation of cancer using image-guided, minimally invasive techniques, including ablation, embolization, and radiation-based therapies. These procedures offer benefits such as reduced hospital stays, lower complication risks, and faster recovery, making them increasingly preferred over conventional open surgeries.
Impact of COVID-19 on the Market
The interventional oncology market witnessed a temporary decline during the COVID-19 pandemic due to lockdown restrictions, postponed cancer treatments, and reduced hospital visits. Many elective oncology procedures were delayed in 2020, negatively impacting procedural volumes.
However, with the lifting of restrictions, hospital visits for cancer diagnosis and treatment increased significantly in 2021, compensating for the delayed procedures. As a result, the market regained momentum and is expected to witness steady growth throughout the forecast period.
Market Trends
Growing Adoption of Radioembolization
One of the most prominent trends in the interventional oncology market is the increasing adoption of radioembolization. This minimally invasive technique delivers radioactive microspheres directly to tumor-feeding blood vessels, offering targeted tumor destruction with minimal damage to surrounding tissues.
Originally developed for liver cancer, radioembolization is now being explored for colorectal cancer and neuroendocrine tumors. In June 2022, research published by the Radiological Society of North America reported a 15-month survival rate in patients undergoing transarterial radioembolization for metastatic colorectal cancer, further supporting its clinical adoption.
Market Growth Drivers
Rising Global Cancer Prevalence
The increasing prevalence of cancer is a major driver of market growth. According to the World Health Organization (WHO), there were approximately 20 million new cancer cases and 9.7 million cancer-related deaths globally in 2020. Common cancers such as liver, lung, breast, and kidney cancers continue to drive demand for effective treatment solutions.
Shift Toward Minimally Invasive Procedures
Patients and healthcare providers are increasingly preferring minimally invasive surgical (MIS) procedures due to advantages such as reduced pain, shorter hospital stays, faster recovery, and lower complication rates. Studies have shown that patients undergoing MIS procedures experience fewer complications compared to open surgery, encouraging wider adoption of interventional oncology techniques.
Market Restraints
Despite strong growth potential, the market faces challenges related to the high cost of interventional oncology procedures and devices. Advanced imaging systems, embolization devices, and ablation technologies require significant capital investment. Additionally, the shortage of trained interventional oncologists, especially in developing regions, limits market penetration and patient access to advanced treatments.
By Type
Radiation therapy devices dominated the market with a 49.48% share in 2026, supported by rising cancer-related hospitalizations. Embolization devices are expected to register the highest CAGR due to their precision and effectiveness.
By Cancer Type
The liver cancer segment held the largest market share at 59.70% in 2026, driven by high adoption of embolization and ablation therapies.
By End User
Hospitals dominated the market with a 67.34% share in 2026, owing to increasing patient admissions and availability of advanced treatment infrastructure.
Key Industry Players
Major companies include Boston Scientific Corporation, Siemens Healthineers, Terumo Corporation, Merit Medical Systems, BD, and AngioDynamics. Product innovation and regulatory approvals remain key growth strategies.
Conclusion
The global interventional oncology market is set to witness robust growth, expanding from USD 2.34 billion in 2025 to USD 4.77 billion by 2034. Rising cancer prevalence, growing preference for minimally invasive procedures, and continuous technological advancements are driving market expansion. Although high treatment costs and limited availability of skilled professionals pose challenges, increasing investments in healthcare infrastructure and innovation are expected to support sustained market growth during the forecast period.
Segmentation By Type
By Cancer Type
By End-User
By Geography